Emv Capital Share Discussion Threads

[kingston78] 15/1/2025 08:19

I am sure that as time passes by, the goal of realisation of one or more of the company's investments is getting closer, ideally in cash on a complete exit. That will reflect the low market cap in relation to its true value. The share price will rise substantially.

[kingston78] 12/1/2025 15:11

The directors did not sell shares in PDSB when it was US$14. Now it is only US$1.41. I hope that the directors are more savvy with the other portfolio companies.

[blakieboy7] 11/1/2025 09:53

Can whoever ticked me down please explain why? I'm all ears

[blakieboy7] 11/1/2025 09:14

PDSB is really struggling at the moment, Frank needs to get a F move on with funding

[loafofbread] 09/1/2025 08:40

A bit of an update on the Ventive website.

Finally listing 2 heat pump options for the home.

Lets hope almost ready to launch the product into the market?

[blakieboy7] 07/1/2025 12:54

I was really hoping for a solid PDSB update. Not sure what's happening with the financing on P3

[blakieboy7] 07/1/2025 10:50

I'm not greedy, I'd be happy with just one Vodaphone equivalent! Ha

[kingston78] 07/1/2025 10:39

In the 1980's Racal Plc spun out various subsidiaries onto the LSE as independent companies, creating enormous value to its shareholders. One of them was Vodafone, which later became the most valuable company in the world at one stage.

Technologies are techniques are improving, enhancing the original inventions.

EMV has a large number of 100% owned and partly owned investments, anyone of which, given the right conditions, could thrive and become a very successful company on their own.

[blakieboy7] 07/1/2025 10:23

Better today

[kingston78] 07/1/2025 09:33

This share is gaining momentum. BUY now for a double in 2025.

The company has been taking a long time to nurture old and new investments with a view of crystallising its gains. I think that it will achieve its aim in 2025. A trade sale or an IPO will do wonders. The sale proceeds could be more than the company's entire market cap.

[loafofbread] 06/1/2025 21:08

Finally moved the bloody bid up from 47p to 52p.

Let's hope that's the last time we see it below the placing price.

Everyone has got the position they want so no excuses for not getting the share price up to where it should be.

[blakieboy7] 06/1/2025 17:40

A better day. Hopefully a lot more blue to come

[kingston78] 06/1/2025 13:33

Panmure Liberum has reduced its share price target from 157p to 149p, which still provides plenty of upside for the share price.

This is the bargain of the year. Sooner or later one or more of the company's investments will be cashed in for significant gain.

[loafofbread] 06/1/2025 11:19

hxxps://www.ii.co.uk/analysis-commentary/five-aim-share-tips-2025-ii533921

EMV one of the 5 tips of the year.

[kingston78] 06/1/2025 11:17

TekCapital is capitalised at nearly £20 M after spinning out a couple of subsidiaries onto the market.

EMV is capitalised at just over £13 M because its portfolio companies are private. EMV should really spin out several subsidiaries onto the stock market.

[kingston78] 03/1/2025 07:11

One of these days one or more of EMV portfolio companies will be far bigger than EMV itself. Mark my words.

[loafofbread] 02/1/2025 23:06

All buys today and options priced at 50p.

[nigelpm] 26/12/2024 22:41

Christ.. stick to the word stuff mate.

[loafofbread] 26/12/2024 21:28

Oak bloke video version of his MKA/ EVAC substack pick

[loafofbread] 23/12/2024 17:43

Looks good.

DEEPTECH RECYCLING ANNOUNCES KEY BOARD APPOINTMENT TO SUPPORT GO-TO-MARKET STRATEGY


London, 23 December.

DeepTech Recycling is pleased to announce the appointment of Simon Ashby-Rudd as Chairman of its Board of Directors.

This strategic move marks a key milestone as the Company accelerates its commercial efforts and enters its next stage of growth.

Simon, a BSc economics graduate of the University College London, brings over 30 years extensive financial experience in the energy sector. His background spans energy investment banking roles at major institutions including Dresden Kleinwort Benson, Citigroup and Standard Bank; as well as senior positions in boutique energy advisory firms such as Tristone Capital and Waterous & Co.

His global experience and leadership in energy finance are crucial as EMV Capital-backed, DeepTech Recycling moves forward with its ambitious plans for growth. The Company is particularly excited to leverage Simon’s expertise as it continues to develop commercial projects in the UK and Europe with customers and partners. The expansion into the European market is a significant step in DeepTech’s journey toward becoming a leading provider of technology solutions for hard-to-recycle plastic waste.

Incoming Chair at DeepTech Recycling, Simon Ashby-Rudd, commented: “I have always been drawn to innovative, cutting-edge energy companies, and DeepTech Recycling offers a truly unique market proposition. I am excited to be working with such a forward-thinking team to drive revenue growth and help establish the Company as a leading force in the sustainable recycling industry. The potential here is enormous, and I look forward to contributing to the next chapter of this exciting journey.”

Marvine Besong, DeepTech’s Managing Director and Chief Technology Officer, said: “Simon’s vast industry network is invaluable as we enter this next phase of growth. He is taking over from Dr. Ilian Iliev, who as Chair helped us redefine our focus and strategy, which culminated in the successful completion of the first phase of a large-scale project with a commercial customer. We are now scaling up our efforts, and Simon’s expertise will play a key role in supporting our commercial ambitions. I would like to extend a warm welcome to Simon from myself and our team.”

Outgoing Chair Dr. Ilian Iliev and CEO of EMV Capital plc, noted “In line with EMV Capital’s Venture Building programme, I joined the company as Chair in its early stages to help the team develop and execute their plan, and mobilise various support resources. As I hand over the role, I am confident that Simon’s expertise and leadership will be invaluable in driving the next phase of the Company’s growth.”

EMV Capital’s investment in the Company was recently recognised with EMV Capital receiving the ‘One to Watch’ Award in the ‘Most Impactful Investment Category’ at the Growth Investor Awards this November. With projects in progress across multiple regions, a growing and highly capable team, and a clear pathway to commercialisation, DeepTech Recycling is poised for continued success as it leads the way toward a more sustainable and circular economy.

[kingston78] 19/12/2024 10:15

TekCapital is valued at £19 million whereas EMV is valued at £11 million.

[blakieboy7] 16/12/2024 13:49

This is why I get frustrated. The company isn't doing everything possible to get the story out there

[loafofbread] 16/12/2024 11:57

Only a week late but ProAxis have finally confirmed they are part of the £55M FMI funding.

No idea why EMV refuse to promote their portfolio.

[loafofbread] 04/12/2024 16:09

Some of you may have seen today's FAB, Fusion antibodies RNS for grant funding that's added 50% to the share price.

Good news is that ProAxis is part of the consortium so with any luck they should receive their own lump of grant funding.

Let's hope they actually release the news rather than keep us in the dark!

£55m shot in the arm for precision medicine in Northern Ireland

Economy Minister Conor Murphy, Wendy Moore, director of data analytics at Diaceutics plc and Professor Sir Ian Greer, vice chancellor, Queen’s University, Belfast



Today at 12:12
Precision medicine in Northern Ireland has received a £55m shot in the arm thanks to a joint effort from industry and academia.
Economy Minister Conor Murphy launched the Future Medicines Institute (FMI) at Queen’s University on Wednesday. It’s backed by £35m from the NI Executive and £20m from NI companies in diagnostics and therapeutics.

The FMI is aimed at driving innovation and production in precision medicine, with the backing of Diaceutics plc, Fusion Antibodies plc, Randox Laboratories, Almac Group, Sonrai Analytics, Exploristics and ProAxsis.

Precision medicine is a branch of healthcare which tailors treatment and drugs to the specific needs of a patient.

Mr Murphy said: “This £55m investment in the FMI is a landmark step for precision medicine in the north which will strengthen our life and health sciences sector and reinforce the region’s role in global healthcare innovation.

“FMI will foster collaboration across industry, academia, and healthcare to accelerate the development of new drugs and diagnostics, driving growth in our economy.



"It will provide a vital pathway to speed up patient access to personalised treatments, streamline drug development processes, and bring innovative solutions to market at pace.”

The £55m is to be used to fund research and development between companies and universities, and to create a shared lab inside Queen’s.